Oric Pharmaceuticals’ Enozertinib Shows 88% Response Rate in EGFR Lung Cancer Study

ORIC Pharmaceuticals presented promising Phase 1b data for enozertinib, an EGFR inhibitor, in NSCLC patients with atypical mutations. The drug showed 84% systemic ORR and 70% intracranial ORR. ORIC plans a global Phase 3 trial in 2027, enrolling 360 patients. Enozertinib was generally well-tolerated. ORIC stock is currently at $12.90, down 5.49%.

Oric Pharmaceuticals reported Phase 1b results for enozertinib, showing 84% systemic and 70% intracranial response rates. The drug was well tolerated. The company plans a global Phase 3 trial, Redwood-1, in 2027, aiming to enroll 360 patients. According to the company, the trial will have dual primary endpoints of ORR and PFS.

Oric Pharmaceuticals, Inc. (ORIC) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Enozertinib Program Update October 23, 2026 Forward-Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this presentation, inc

ORIC Pharmaceuticals reported Phase 1b data for enozertinib in 1L EGFR atypical NSCLC, showing 84% systemic and 70% intracranial ORR. The company plans to start the Phase 3 Redwood-1 trial in 1H 2027. According to ORIC, this marks a transition to late-stage development for enozertinib.

ORIC Pharmaceuticals reported preclinical data indicating its drug rinzimetostat may improve sensitivity to androgen receptor inhibition in prostate cancer, supporting its ongoing Phase 3 trial. The company believes this supports the drug's use across various disease settings.

ORIC Pharmaceuticals presented preclinical and translational data at ESMO Congress 2026, showing that rinzimetostat, its prostate cancer drug, enhances sensitivity to androgen receptor inhibition. The data suggest potential advantages over EZH2 inhibitors, including maintained effectiveness against resistance mutations and a favorable safety profile. ORIC's chief scientific officer highlighted the drug's potential best-in-class profile and its ongoing evaluation in the Himalayas-1 Phase 3 trial.